Please login to the form below

Not currently logged in
Email:
Password:

hGH-CTP

This page shows the latest hGH-CTP news and features for those working in and with pharma, biotech and healthcare.

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer/Opko's long-acting growth hormone misses mark in trial. Previously forecast as a blockbuster product, hGH-CTP fails to show significant change. ... A greater percentage of subjects on hGH-CTP normalised serum concentrations of insulin-like growth

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

  • Pharma deals during December 2014 Pharma deals during December 2014

    This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... for adult GHD but for paediatric GHD, the royalties will transition to gross profit sharing for both hGH-CTP and Pfizer's Genotropin.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics